RACs RC220 Demonstrates Safety in Peripheral Infusion According to Preclinical Models

Race Oncology Limited (ASX: RAC) has confirmed the successful completion of preclinical studies indicating that their innovative bisantrene formulation, RC220, prevents drug crystallization and vein inflammation (phlebitis) during peripheral vein infusions. Bisantrene (RC110) traditionally required invasive central venous catheters and hospital settings, mainly for hematological cancers. However, RC220 allows peripheral intravenous administration, often preferred for solid tumors like breast cancer, offering patients a higher quality of life with reduced risks and disruptions.

This method enables treatments outside major hospitals, even at home, enhancing patient convenience. Additionally, RC220's precise dosing capabilities, vital in chemotherapy, are simpler through peripheral IV infusion, ensuring accurate treatment. The successful preclinical models endorse RC220, supporting its use in human clinical trials for conditions requiring peripheral infusions. This advancement not only holds significant intellectual property value but also enhances convenience for both patients and clinicians.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com